SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Drug Safety Risks: Levi & Korsinsky

NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between March 26, 2025 and November 4, 2025. Find out if you qualify to recover losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500. The lawsuit contends that Soleno's Phase 3 clinical trial program for DCCR (marketed as VYKAT XR) systematically ...